



Tularik Contacts:
Traci McCarty
Investors/Media
(650) 825-7182

Tularik Receives \$35 million from Amgen Following Hart-Scott-Rodino Clearance

South San Francisco, Calif. – July 1, 2003 - Tularik Inc. (Nasdaq: TLRK) announced today that it has received \$35 million from the purchase by Amgen Inc. (Nasdaq: AMGN) of Tularik stock. Under the terms of the previously-announced stock purchase agreement, Amgen purchased 3.5 million shares of newly-issued Tularik common stock at \$10 per share. The closing of this transaction follows the early termination by the United States Federal Trade Commission of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Over the next three years, Amgen will purchase an additional \$40 million in newly-issued Tularik common stock at then market prices.

On May 21, Tularik and Amgen announced they had signed an agreement to collaborate on the discovery, development and commercialization of therapeutics aimed at oncology targets. Within the next week, Tularik expects to receive from Amgen an additional \$10 million, representing the first installment of annual research support for the oncology collaboration. In aggregate, Tularik will receive \$125 million in committed funding under the terms of these agreements.

In a separate transaction, Amgen has previously purchased 6 million shares of Tularik's outstanding common stock from ZKB Pharma Vision AG. With the early termination of the Hart-Scott-Rodino waiting period, Amgen will purchase an additional 3 million shares of Tularik stock from ZKB Pharma Vision AG. In combination with the initial shares purchased as part of the oncology collaboration, Amgen will hold a 21.2% stake in Tularik.

About Tularik

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. The Company currently has four drug candidates in clinical trials. In the cancer area, Tularik is currently

conducting a pivotal study of T67 for the treatment of hepatocellular carcinoma (HCC) and Phase 2 trials with T607 for the treatment of HCC, ovarian cancer, gastric cancer and esophageal cancer. T487, for the treatment of inflammatory diseases, and T131, for the treatment of type 2 diabetes, are in Phase 1 trials to evaluate safety and pharmacokinetic parameters. For more information, visit Tularik's Internet website at www.tularik.com.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Tularik to differ materially from those indicated by these forward-looking statements, including, among others, risks implicit in the collaboration with Amgen and risks detailed from time to time in Tularik's SEC reports, including the report on Form 10-Q for the quarter ended March 31, 2003. Tularik does not undertake any obligation to update forward-looking statements.